A Phase 2 interventional study of BIO 300 Oral Suspension and Placebo in COVID-19, Long COVID and Pulmonary Fibrosis, sponsored by Humanetics Corporation. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Humanetics Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Post-Acute COVID-19 Syndrome with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 81st largest by planned enrollment of the 155 interventional ones that give a count, is one of 6 that started in 2020, is one of 47 in phase 2, reaches primary completion later than 1 of the 83 other live ones, and was the 2nd registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →62 of the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Stephanie B. Seminara, MD · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 53 · Phase 3 13 · Phase 4 4
First in 2020; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 52 across the 155 interventional studies, 155 across the 37 observational. Of the 96 that completed or were terminated, 30 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 194 have an industry lead sponsor. The 10 most frequent:
Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Humanetics Corporation has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
30 of the studies in Post-Acute COVID-19 Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06974084Phase 3HealthBio, Inc.A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | 2026-12-01 |
| NCT06960928Phase 3Icahn School of Medicine at Mount SinaiLow Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 | 2026-12-31 |
| NCT06511063Icahn School of Medicine at Mount SinaiAntiviral Clinical Trial for Long Covid-19 | 2026-11 |
Add all 30 to your calendar (.ics) → With an account.
Among the 194 studies in Post-Acute COVID-19 Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's planned enrollment of 50 is below the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.
Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Blood routine, liver and kidney function test values are within the controllable range
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BIO 300 Oral Suspension (genistein 1500 mg) will be self-administered daily for 7 days each week for 12 weeks.
Drug: BIO 300 Oral Suspension
BIO 300 Oral Suspension matched placebo will be self-administered daily for 7 days each week for 12 weeks.
Drug: Placebo
Suspension of genistein nanoparticles
Matched placebo for BIO 300 Oral Suspension
Change in DLCO
Diffusing capacity of the lungs for carbon monoxide (DLCO)
Time frame: 12 Weeks
Change in 6 Minute Walk Test
6 minute walk test (6MWT)
Time frame: 12 Weeks
Change in FVC
Forced vital capacity (FVC)
Time frame: 12 Weeks, 6 Months and 12 Months
Change in St. George's Respiratory Questionnaire (SGRQ) Scores
Patient reported outcome to measure impact on overall health, daily life, and perceived well-being in patients with impaired pulmonary function. Scores range from 0-100 with higher scores indicating more limitations.
Time frame: 12 Weeks, 6 Months and 12 Months
Change in Pulmonary Fibrosis on HRCT Scan
Evidence of pulmonary fibrosis on high resolution computerized tomography (HRCT) scans of the lungs based on a 4-point Likert scale, where 0 is no evidence of fibrosis and 3 is severe fibrosis
Time frame: 12 Weeks, 6 Months and 12 Months
Incidence of Re-Hospitalization
Incidence of hospitalization after initial discharge and initiating treatment
Time frame: 12 Months
All-Cause Mortality
Mortality at 12 months after initiating treatment
Time frame: 12 Months
Change in FEV1
Forced expiratory volume in one second (FEV1)
Time frame: 12 Weeks, 6 Months and 12 Months
Change in FEV1/FVC Ratio
Ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC)
Time frame: 12 Weeks, 6 Months and 12 Months
Change in 6 Minute Walk Test
6 minute walk test (6MWT)
Time frame: 6 Months and 12 Months
Change in Pulse Oximetry at Rest and During the 6MWT
Oxygen saturation (pulse oximetry) at rest and during the 6 minute walk test (6MWT)
Time frame: 12 Weeks, 6 Months and 12 Months
Change in DLCO
Diffusing capacity of the lungs for carbon monoxide (DLCO)
Time frame: 6 Months and 12 Months
Adverse Events Related to BIO 300 Oral Suspension
Evaluate the safety of BIO 300 Oral Suspension treatment
Time frame: 12 Months
Change in Clinical Laboratory Values
Monitoring of blood serum levels for bilirubin, C-reactive protein (CRP), creatinine, blood urea nitrogen (BUN), cholesterol and triglycerides (all reported as mg/dL)
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Change in Clinical Laboratory Values
Monitoring of blood serum levels for troponin T, d-dimer and ferritin (all reported as ng/mL)
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Change in Clinical Laboratory Values for Albumin
Monitoring of blood serum levels for albumin (g/dL)
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Change in Clinical Laboratory Values for Serum Enzymes
Monitoring of blood serum levels for alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) (all reported as Units/L)
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Change in Complete Blood Counts with Differential
Monitoring of white blood cell, red blood cell and platelet counts
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Change in Supplemental Oxygen Use
Prescribed supplemental oxygen flow rate at night, rest and exertion
Time frame: 12 Weeks, 6 Months and 12 Months
Change in Duration of Supplemental Oxygen Use
Duration of supplemental oxygen use
Time frame: 12 Weeks, 6 Months and 12 Months
Change in Serum Cytokine Expression
Expression levels of serum-derived cytokines (IL-1b, IL-6, IL-8, TNFa, and TGFb1)
Time frame: 4 Weeks, 8 Weeks, 12 Weeks, 6 Months and 12 Months
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in Jul 2024, 44 months.
Of 63 phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Genistein-based BIO 300
Post-Acute COVID-19 Syndrome →
Humanetics Corporation